Regulatory
Tetraphase Pharmaceuticals’ Xerava (eravacycline) Receives FDA’s Approval for Complicated Intra-Abdominal
Shots: The approval is based on the two P-III IGNITE study assessing Xerava (eravacycline, bid, IV) vs ertapenem & meropenem in patients with cIAI The study demonstrated a non-inferiority data […]readmore